Elevance Health (ELV) stock
NYSE
As of the Nov 16, 2026 close (U.S. Eastern)
- Market cap
- $96.4B
- As of Nov 16, 2026
- P/E
- 18.76x
- Trailing twelve months
- P/B
- 2.16x
- Latest reported equity
- P/S
- 0.48x
- Trailing twelve months
- ROE
- 11.5%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- $96.4B
- As of Nov 16, 2026
- P/E
- 18.76x
- Trailing twelve months
- P/B
- 2.16x
- Latest reported equity
- P/S
- 0.48x
- Trailing twelve months
- ROE
- 11.5%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
18.76x
P/B
2.16x
P/S
0.48x
Earnings and dividend metrics▾
Earnings
EPS
$23.79
Earnings per share
BPS
$206.86
Book value per share
ROE
11.5%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $23.79 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $206.86 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 11.5%.
Dividends
Dividend per share
$7.08
Payout ratio
29.8%
Dividend per share and payout ratio are for fiscal 2025.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $708.00 before tax.
- Payout ratio — 29.8% of earnings was paid out as dividends.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 1.4% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $50.7B+1.4%
$45.1B
Jul–Sep '24
$50.7B
Jul–Sep '25
$51.4B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 21, 2026.
- Earnings per share increased 17.9% from the same quarter a year earlier.
- Revenue increased 1.4% from the same quarter a year earlier.
- Operating income decreased 2.0% from the same quarter a year earlier.
- Net income increased 14.8% from the same quarter a year earlier.
Filed Oct 21, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- LAVU RATNAKAREVP & Chief Digital Info Ofr · Nov 5, 2026Open-market sale1,300 shares · $572KAvg. price $44014,849 shares held after
- Kaye MarkEVP & CFO · Oct 22, 2026Open-market sale10,584 shares · $4.7MAvg. price $440.132
Show 13 price lots
- 2,343 shares × $441.34$1.0M
- 1,720 shares × $440.44$758K
- 1,660 shares × $436.2$724K
- 1,160 shares × $439.25$510K
- 827 shares × $446.05$369K
- 560 shares × $437.07$245K
- 480 shares × $442.61$212K
- 440 shares × $443.81$195K
- 400 shares × $434$174K
- 321 shares × $435.25$140K
- 273 shares × $447.19$122K
- 240 shares × $438.22$105K
- 160 shares × $444.85$71K
- Kaye MarkEVP & CFO · Oct 2, 2026Shares withheld for taxes4,161 shares · $1.6MAvg. price $386.4327,876 shares held after
- Kaye MarkEVP & CFO · Oct 2, 2026Grant or award2,627 shares · $0Avg. price $030,503 shares held after
- Wessling Erin MEVP & Chief Legal Officer · Sep 3, 2026Shares withheld for taxes255 shares · $106KAvg. price $414.787,230 shares held after
- Craig Ryan REVP & Chief HR Officer · Sep 2, 2026Shares withheld for taxes144 shares · $58KAvg. price $405.846,530 shares held after
- Wessling Erin MEVP & Chief Legal Officer · Sep 2, 2026Shares withheld for taxes94 shares · $38KAvg. price $405.847,485 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KElevance Health said operating revenue for Q3 2026 was $50.4 billion, up 0.7% from 3Q 2025. Diluted EPS was $6.27 and adjusted diluted EPS was $6.99.Published Oct 21, 2026 · Filed Oct 21, 2026Read the summary →
- AI summary8-KElevance Health said its officers expect to speak with investors and analysts this week and will reaffirm the company's shareholders' earnings guidance for full year 2026 to be at least $19.85 per diluted share, including approximately $6.90 per diluted share of net unfavorable items.Published Oct 1, 2026 · Filed Jun 10, 2026Read the summary →
- AI summary8-KElevance Health said it held its Annual Meeting of Shareholders on May 13, 2026, with 194,441,339 shares of common stock represented, constituting a quorum.Published Oct 1, 2026 · Filed May 13, 2026Read the summary →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Elevance Health (ELV) stock information
NYSE
Elevance Health (ELV) is listed on NYSE. Its market capitalization is about $96.4B. On trailing-twelve-month earnings the P/E ratio is 18.76, and the P/B ratio is 2.16. Return on equity is 11.5%. These figures are computed in-house from official filings and are reference information only.
Elevance Health — frequently asked questions
- What is the P/E ratio of Elevance Health (ELV)?
- On a trailing-twelve-month basis, ELV trades at a P/E ratio of 18.76. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Elevance Health?
- ELV has a market capitalization of about $96.4B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.